Tengion Announces Change to Board of Directors

                Tengion Announces Change to Board of Directors

PR Newswire

WINSTON-SALEM, N.C., Dec. 21, 2012

WINSTON-SALEM, N.C., Dec. 21, 2012 /PRNewswire/ --Tengion, Inc. (OTCQB:
TNGN), a leader in regenerative medicine, today announced that Scott D. Flora,
President & Chief Executive Officer at OmniGuide, has resigned from Tengion's
Board of Directors, effective December 19, 2012.

"Scott has been a valuable asset to Tengion and his expertise in the medical
and surgical device arenas has been an excellent resource for the Company over
the last year," reflected David Scheer, Chairman of the Tengion Board of
Directors. "We are very appreciative of Scott's service and support and we
wish him well in his future endeavors."

"It has been a pleasure to serve on the Tengion Board and work with this
outstanding team," commented Scott Flora. "The Company has made significant
progress in the 14 months that I have sat on the Board and I look forward to
watching their continued success."

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on
developing its Organ Regeneration Platform™ to harness the intrinsic
regenerative pathways of the body to regenerate a range of native-like organs
and tissues with the goal of delaying or eliminating the need for chronic
disease therapies, organ transplantation, and the administration of
anti-rejection medications. An initial clinical trial is ongoing for the
Company's most advanced product candidate, the Neo-Urinary Conduit™, an
autologous implant that is intended to catalyze regeneration of native-like
urinary tissue for bladder cancer patients requiring a urinary diversion
following bladder removal. The Company's lead preclinical candidate is the
Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney
transplantation by increasing renal function in patients with advanced chronic
kidney disease. Tengion has worldwide rights to its product candidates.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to: (i) plans to develop and commercialize its
product candidates, including the Neo-Kidney Augment and the Neo-Urinary
Conduit; and (ii) expectations regarding ongoing and planned preclinical
studies and clinical trials. Although Tengion believes that these statements
are based upon reasonable assumptions within the bounds of its knowledge of
its business and operations, there are a number of factors that may cause
actual results to differ from these statements. Tengion's business is subject
to significant risks and uncertainties and there can be no assurance that
actual results will not differ materially from expectations. Factors which
could cause actual results to differ materially from expectations include,
among others: (i) the FDA could place the Neo-Urinary Conduit clinical trial
on clinical hold; (ii) patients enrolled in the Neo-Urinary Conduit clinical
trial may experience adverse events, which could delay the clinical trial or
cause the Company to terminate the development of its Neo-Urinary Conduit;
(iii) the Company may have difficulty enrolling patients in its clinical
trials, including the Phase 1 clinical trial for the Neo-Urinary Conduit; (iv)
data from the Company's ongoing preclinical studies, including the proposed
GLP program for the Neo-Kidney Augment, may not continue to be supportive of
advancing such preclinical product candidates; and (v) the Company may be
unable to progress its product candidates that are undergoing preclinical
testing, including the Neo-Kidney Augment, into clinical trials and the
Company may not be successful in designing such clinical trials in a manner
that supports development of such product candidates. For additional factors
which could cause actual results to differ from expectations, reference is
made to the reports filed by the Company with the Securities and Exchange
Commission under the Securities Exchange Act of 1934, as amended. The forward
looking statements in this release are made only as of the date hereof and the
Company disclaims any intention or responsibility for updating predictions or
expectations in this release.



SOURCE Tengion, Inc.

Website: http://www.tengion.com
Contact: Investor and Media Contact, Brian Davis, brian.davis@tengion.com,
+1-267-960-4802